Investigator Sponsored Trials
Karyopharm is committed to supporting independent research that is aligned with Karyopharm areas of research interest.
Independent research may be defined within the industry as Investigator Sponsored Research (ISR), Investigator Initiated Research (IIR), Investigator Sponsored Trials (IST) or Investigator Initiated Trials (IIT) and Outcomes Research (OR). Karyopharm considers all independent research to be part of its Global Medical Research (GMR) program.
Selinexor in Multiple Myeloma
Areas of Interest
- The use of selinexor-triplet therapy peri-T-cell engager (clinical and mechanistic)
- Selinexor in patients with relapse refractory multiple myeloma of high unmet need (e.g., renal insufficiency, extramedullary disease)
- Real-world evidence on selinexor-based triplet therapy dosing and sequencing patterns
Out of Scope
- Front line newly diagnosed multiple myeloma
- Combination therapy with small molecules
- Eltanexor in multiple myeloma
Selinexor in Endometrial Cancer
Areas of Interest
- Selinexor ± Immuno-Oncology regardless of setting
- Selinexor in combination with additional novel agents (e.g., ADCs)
- Selinexor in combination with chemotherapy in advanced/recurrent 1L
Out of Scope
- Eltanexor in endometrial cancer
- Selinexor monotherapy as 1L treatment in advanced/recurrent
Selinexor in Myelofibrosis
Areas of Interest
- Selinexor in subpopulations of high unmet need in myelofibrosis (e.g., MDS/MPN overlap, JMML)
- Doublet or triplet combination therapy with novel myelofibrosis agents
- Preclinical biomarkers of response
Out of Scope
- Eltanexor in myelofibrosis
- Selinexor in JAKi failure, intolerance, or suboptimal response
- Selinexor in combination with pacritinib
Eltanexor
Disease Areas
- Polycythemia Vera
- Chronic Myelomonocytic Leukemia
- Diffuse large B cell lymphoma
Biomarker Guided
- TP53 WT (e.g., low grade ovarian, kidney, liver, esophageal, lung, pancreatic, and/or bladder)
Out of Scope
- Sarcoma
- Non-small cell lung cancer
- Melanoma
- Acute myeloid leukemia
- Glioblastoma
Other areas of interest
- Selinexor in underrepresented patient populations
- Selinexor in pediatric patients with malignancy
IST proposals should investigate clinical endpoints. Preclinical research should be correlative and supportive in nature.
Investigators from the scientific and academic research communities may submit a proposal for Global Medical Research (GMR) through our online portal called PORE®. Karyopharm may provide support of independent research in the form of drug supply only or drug supply with funding. This program is open to physicians, researchers and institutions interested in conducting independent research.
All research proposals should be submitted via our PORE® Request Management System. Preliminary discussions on research proposals are welcome. Please contact your local MSL or the Karyopharm GMR team. Contact IST.Operations@Karyopharm.com to initiate a discussion on a research proposal.
Through the Karyopharm internal review process, independent and unsolicited research proposals are periodically reviewed for scientific merit and alignment with our clinical development strategy, among other factors.
Additional information regarding the submission requirements can be found within PORE®. You may also submit any further GMR related questions to IST.Operations@Karyopharm.com.
Submission of a proposal does not imply nor guarantee endorsement. Any Karyopharm support is contingent upon an executed research agreement and the terms therein.